EGFR and cancer: Although other EGFR inhibitors, such as small tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib) are available for the treatment of other tumor types; only modest response rates of up to 11% as monotherapy have been obtained in H and N cancers [11, 12].